The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

被引：0
|
作者：
Kongju Wu
Ming Yi
Shuang Qin
Qian Chu
Xinhua Zheng
Kongming Wu
机构：
[1] Medical School of Pingdingshan University,Department of Clinical Medicine
[2] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital of Tongji Medical College
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Immunotherapy; PD-1; PD-L1; CTLA-4; Immune checkpoint inhibitor; Combination therapy; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors
    Devaux, Alix
    Baurain, Jean-Francois
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (02) : 123 - 130
  • [42] Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
    Shen, Kaikai
    Cui, Jinggang
    Wei, Yuqing
    Chen, Xiaojun
    Liu, Guohua
    Gao, Xiaolai
    Li, Wei
    Lu, Huiling
    Zhan, Ping
    Lv, Tangfeng
    Lin, Dang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6636 - 6652
  • [43] Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.
    Wang, Daniel Ying
    Kim, Dae Won
    Shah, Neil J.
    Conry, Robert Martin
    Mehta, Rutika Jitesh
    Silk, Ann W.
    Zhou, Alice
    Voorhees, Amber L.
    Mckee, Svetlana B.
    Norrell, Jacqueline
    Mehnert, Janice M.
    Puzanov, Igor
    Gibney, Geoffrey Thomas
    Rapisuwon, Suthee
    Eroglu, Zeynep
    Johnson, Douglas Buckner
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
    Qian, Da
    Xu, Yuhao
    Wu, Yihao
    Qiu, Jie
    Hong, Weimin
    Meng, Xuli
    CHINESE MEDICAL JOURNAL, 2023, 136 (14) : 1663 - 1670
  • [45] Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
    Goepfert, Katrin
    Dinsart, Christiane
    Rommelaere, Jean
    Foerster, Friedrich
    Moehler, Markus
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [46] Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma
    Feng, Zhichao
    Rong, Pengfei
    Wang, Wei
    GUT, 2020, 69 (10) : 1904 - 1906
  • [47] Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
    Huang, Shibo
    Huang, Yanping
    Li, Chunyan
    Liang, Yiwen
    Huang, Miaoyan
    Luo, Raoshan
    Liang, Weiming
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [48] The Efficacy and Safety of PD-1/PD-L1 Inhibitors for Advanced Refractory Esophageal and GE Junction Cancer: A Meta-Analysis
    Li, Tian
    Zou, Yuntao
    Li, Yiting
    Friedenberg, Frank
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S346 - S346
  • [49] Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
    Qian Da
    Xu Yuhao
    Wu Yihao
    Qiu Jie
    Hong Weimin
    Meng Xuli
    中华医学杂志(英文版), 2023, 136 (14)
  • [50] Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
    Zhenzi Wang
    Yuan Liu
    Kedi Wang
    Liyan Ma
    BMC Gastroenterology, 24 (1)
12345